Acurx Pharmaceuticals (NASDAQ:ACXP) Stock Price Down 0.3%

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXPGet Rating)’s share price traded down 0.3% on Tuesday . The stock traded as low as $3.51 and last traded at $3.63. 6,462 shares changed hands during trading, a decline of 73% from the average session volume of 23,630 shares. The stock had previously closed at $3.64.

The stock has a market capitalization of $37.25 million and a P/E ratio of -2.39. The company’s 50 day simple moving average is $3.29 and its two-hundred day simple moving average is $3.76.

Acurx Pharmaceuticals (NASDAQ:ACXPGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.07.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACXP. BlackRock Inc. bought a new stake in shares of Acurx Pharmaceuticals during the third quarter valued at approximately $33,000. Millennium Management LLC bought a new stake in shares of Acurx Pharmaceuticals during the third quarter valued at approximately $155,000. Finally, Patriot Financial Group Insurance Agency LLC grew its stake in shares of Acurx Pharmaceuticals by 75.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 7,000 shares of the company’s stock valued at $30,000 after purchasing an additional 3,000 shares during the last quarter. 0.72% of the stock is currently owned by institutional investors and hedge funds.

Acurx Pharmaceuticals Company Profile (NASDAQ:ACXP)

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.